Parkwood LLC maintained its position in shares of KemPharm, Inc. (NASDAQ:KMPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,809 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Parkwood LLC owned 0.86% of KemPharm worth $503,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in KMPH. Creative Planning increased its position in shares of KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock valued at $2,223,000 after buying an additional 10,200 shares in the last quarter. C WorldWide Group Holding A S increased its position in shares of KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock valued at $890,000 after buying an additional 16,699 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of KemPharm during the first quarter valued at approximately $647,000. Finally, Bank of New York Mellon Corp increased its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares in the last quarter. Institutional investors and hedge funds own 43.60% of the company’s stock.
Shares of KemPharm, Inc. (NASDAQ KMPH) opened at 3.00 on Friday. The firm’s 50 day moving average is $3.38 and its 200-day moving average is $3.90. The company’s market cap is $43.97 million. KemPharm, Inc. has a 1-year low of $2.45 and a 1-year high of $5.47.
COPYRIGHT VIOLATION WARNING: “Parkwood LLC Has $503,000 Position in KemPharm, Inc. (NASDAQ:KMPH)” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/parkwood-llc-continues-to-hold-position-in-kempharm-inc-nasdaqkmph-updated-updated.html.
KMPH has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Canaccord Genuity set a $7.00 target price on shares of KemPharm and gave the stock a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $13.00 target price on shares of KemPharm and gave the stock a “buy” rating in a research note on Wednesday, May 10th. ValuEngine raised shares of KemPharm from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 1st. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $8.00 target price on shares of KemPharm in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. KemPharm presently has an average rating of “Buy” and an average target price of $8.10.
In other news, CEO Travis C. Mickle purchased 8,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were acquired at an average price of $3.45 per share, with a total value of $27,600.00. Following the acquisition, the chief executive officer now directly owns 1,629,612 shares in the company, valued at $5,622,161.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 10,775 shares of company stock worth $38,783. Insiders own 22.80% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
What are top analysts saying about KemPharm Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for KemPharm Inc. and related companies.